Today's Rundown - No sleep, exiled mattresses, cleared bank accounts: Getting deals done at JPM
- Pfizer CEO Bourla teases cost cuts ahead—sooner rather than later
- Want clues into Gilead's M&A strategy? Check out last year's Galapagos deal
- 4 women discuss culture shock between Big Pharma, smaller biotech and their first CEO role
- Bristol chief says one-third of Celgene cost cuts will hit in 2020
- Roche, Illumina unveil 15-year cancer diagnostic tie-up
- JetBlue, but for biopharma: Borisy's EQRx nabs $200M, takes aim at drug prices
- With new ethics plan, Novartis chief puts his money where his mouth is
- Already prepping for Alzheimer's launch, Biogen scouts 'top talent' and talks pricing
- Synlogic CEO Brennan on lessons learned and what's up in 2020
- With Tesaro staff and expertise in the mix, GSK gears up for 3 oncology launches in 2020
- Esperion tees up to launch cholesterol-busting meds—at affordable prices
- As the biotech world makes San Francisco home for the week, Janssen has longer-term plans
- Ivenix taps new CEO as it brings its digital infusion pump to market
Featured Story | | | Monday, January 13, 2020 We're always looking to ask the big questions at FierceBiotech, and, at this year's J.P. Morgan Healthcare Conference, we're asking: Where do all the orphaned mattresses go? Stick with us; it's a story of dealmaking madness at the biggest biopharma conference of the year. |
|
|---|
|
 | Thank you to Rho for sponsoring this year's JPM 2020 coverage. |
Top Stories Wednesday, January 15, 2020 Every drugmaker has three core units: R&D, manufacturing and commercial. But then there are what Pfizer CEO Albert Bourla calls “enabling functions”—think HR and digital—and that’s where he sees room for his company to cut costs. Tuesday, January 14, 2020 After taking the reins at Gilead early last year, CEO Daniel O’Day’s been heading up the company long enough to understand what investors really want: more transparency and M&A clues. He gave them both Monday at the J.P. Morgan Healthcare Conference. Wednesday, January 15, 2020 At this year’s J.P. Morgan Healthcare Conference, we caught up with four women who had moved up the ranks in biopharma and are leading companies in their first CEO role: Synlogic's Aoife Brennan, Turning Point's Athena Countouriotis, Cygnal's Pearl Huang and Lyndra's Patricia Hurter. Monday, January 13, 2020 Last year, Bristol-Myers Squibb stole the show at the J.P. Morgan Healthcare Conference with its $74 billion deal agreement for Celgene. But one year later, with the deal just recently closed, company CEO Giovanni Caforio says he feels “even better about our opportunity” then he did when BMS unveiled it. Monday, January 13, 2020 Roche has inked a 15-year partnership with Illumina in oncology, which will include collaborating on new companion diagnostic indications for the DNA sequencing giant’s pan-cancer assay. Sunday, January 12, 2020 It's not news: Over time, biopharma companies have raised the price of new medicines ever higher—simply because they can, says veteran biotech investor Alexis Borisy. Now, he’s throwing a wrench in the system with a new kind of biotech company, one that will “reshape the industry” by introducing new medicines at “radically lower” prices. Monday, January 13, 2020 Novartis' history of scandals—and apologies for those scandals—might make anyone skeptical of CEO Vas Narasimhan's pledge to make trust a top priority. But now, the company is taking the promise a step further. Into Narasimhan's own pocket, in fact. Tuesday, January 14, 2020 Biogen hasn't even filed its FDA application for controversial Alzheimer's drug aducanumab yet. But it's already started gearing up for a launch, recruiting across biopharma for "top talent" for its rollout teams, building up manufacturing and talking to experts about one key number—price. Tuesday, January 14, 2020 Last August, Synlogic pulled the plug on its lead program: a “synthetic biotic,” or living microbe medicine, aimed at lowering ammonia levels in the intestine. Now, CEO Dr. Aoife Brennan is sharing what the company learned from that failure and what it means for Synlogic’s future. Tuesday, January 14, 2020 Zejula wasn't the only asset that came to GlaxoSmithKline with its Tesaro buyout, CEO Emma Walmsley said Tuesday at the J.P Morgan Healthcare Conference. It also picked up experts in cancer R&D and regulatory affairs, plus a "talented and competitive" sales team—and GSK can leverage that brain trust with three cancer launches this year. Tuesday, January 14, 2020 With approvals looming for two cholesterol-busting drugs, Esperion is building a team of 300 sales reps to make sure doctors know to prescribe the new drugs to patients who struggle to control their cholesterol. And it plans to sell the drugs at a price that ensures patients prescribed them can actually afford them. Monday, January 13, 2020 As the annual J.P. Morgan Healthcare Conference kicks off in San Francisco this week, Janssen has unveiled plans to double down on its own long-term presence in the area. Monday, January 13, 2020 Ivenix brought on a medtech veteran to be its new CEO as the manufacturer prepares to bring its next-generation infusion pump to the market. The Boston-based company tapped Jorgen Hansen to be its next chief, after securing a 510(k) clearance from the FDA in June 2019. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|---|
|
Resources Sponsored by: Benchling As emerging modalities transform the needs of life science R&D, how can biotech and pharma companies use modern software approaches to increase productivity and reach breakthroughs faster? Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: ICON Clinical Research Ltd The beginning of this digital transformation is well underway and is likely to accelerate. Read our white paper, “Digital Disruption in Biopharma: How Digital Transformation can reverse declining ROI on R&D,” to learn more. Sponsored by: snapIoT, Inc. Download this white paper and read the expert feedback that snapIoT has gathered from industry thought leaders on the evolution, evaluation, and use of telemedicine solutions in clinical trials. Sponsored by: EVERSANA How are your launch strategies can convert “innovation” into value for patients? Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks Sponsored by: Outer Edge Technology, LLC Why companies leverage the expertize of industry focused cloud service providers to design and build quality systems and facilitate the FDA Validation of Mission Critical Apps in the Cloud. Sponsored by: Colorcon Learn more: Best practices for defending supply chain security and compliance by efficiently managing product authentication. Sponsored by: Metabolon Small or emerging pharmaceutical and biotech companies pursuing novel molecules and targets have two important goals: achieve clinical success and attract new rounds of funding. While there’s never a guarantee of either, certain actions can influence the outcome in your favor. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. |
|
